Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhiyue Rao, Chunmei Bai(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuli Ding, Bo Jin(Chengdu Medical College), Ying Cheng(Yunnan University), Zhaoxia Dai(Dalian Medical University), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Yu Yao(Qinghai University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital), Xingya Li(First Affiliated Hospital of Zhengzhou University), Yanqiu Zhao(Harbin Medical University), Yinxiang Wang(Betta Pharmaceuticals (China)), Changlu Hu(Anhui Provincial Hospital), Zhe Liu(Capital Medical University), Yanping Hu(Chinese People's Liberation Army), Dongqing Lv(Wenzhou Medical University), Hui Zhao(Anhui Medical University), Jianping Xiong(Nanchang University), Lin Wu(Materials Systems (United States)), Zhi‐Hua Li(Sun Yat-sen University), Yongsheng Wang(Guangzhou University of Chinese Medicine), Yongsheng Li(First People's Hospital of Yunnan Province), Qingshan Li(Chengde Medical University), Zhihua Liu(Shanghai Jiao Tong University), Zhen Wang(Ministry of Education), Xueqin Chen(Jinan University), Jun Zhao(Beijing Institute of Technology), Rui Ma(First Hospital of China Medical University), Qiao Li(Zhengzhou University of Light Industry), Guohao Xia(Jiangsu Cancer Hospital), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Runxiang Yang(Kunming Medical University), Weiguo Hu(Ruijin Hospital), Jin Zhou(Sichuan Cancer Hospital), Yanhong Shang(Affiliated Hospital of Hebei University), Qitao Yu(Guangxi Medical University), Ligang Xing(Affiliated Hospital of Southwest Medical University), Enfeng Zhao, Wu Zhuang(Hunan University), Yan Yu(Binzhou Medical University), Jian Fang, Zhengbo Song(Zhejiang Cancer Hospital), Guangyu An(Yang Hospital), Kejing Tang, Jian Zhang(Fudan University Shanghai Cancer Center), Andrea Wang‐Gillam(Washington University in St. Louis), Lian Liu, Yanhong Gu(Nanjing Medical University)
Cited by 30
Related Papers
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer
|Molecular Cancer|2020|1k
Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses
|Cancer Research|2012|941
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914